Juno Therapeutics Inc. (JUNO)

86.96
0.09 0.10
Prev Close 86.87
Open 86.97
Day Low/High 86.90 / 87.01
52 Wk Low/High 19.62 / 87.01
Volume 3.70M
Avg Volume 4.51M
Exchange
Shares Outstanding 116.11M
Market Cap 10.10B
EPS -4.10
Div & Yield N.A. (N.A)
Robbins Arroyo LLP: Juno Therapeutics, Inc. (JUNO) Misled Shareholders According To A Recently Filed Class Action

Robbins Arroyo LLP: Juno Therapeutics, Inc. (JUNO) Misled Shareholders According To A Recently Filed Class Action

Shareholder rights law firm Robbins Arroyo LLP announces that a class action complaint was filed against Juno Therapeutics, Inc.

SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Juno Therapeutics Inc. And Reminds Investors With Losses To Contact The Firm

SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Juno Therapeutics Inc. And Reminds Investors With Losses To Contact The Firm

Lundin Law PC announces a class action lawsuit has been filed against Juno Therapeutics Inc.

Juno Therapeutics Adds Adenosine Receptor Antagonist Through Acquisition Of RedoxTherapies

Juno Therapeutics Adds Adenosine Receptor Antagonist Through Acquisition Of RedoxTherapies

Juno Therapeutics, Inc. (Nasdaq: JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, announced today that it has acquired RedoxTherapies, Inc.

Glancy Prongay & Murray Announces The Filing Of A Securities Class Action On Behalf Of Juno Therapeutics, Inc. Investors And Encourages Investors To Contact The Firm

Glancy Prongay & Murray Announces The Filing Of A Securities Class Action On Behalf Of Juno Therapeutics, Inc. Investors And Encourages Investors To Contact The Firm

Glancy Prongay & Murray LLP ("GPM") announces that a class action lawsuit has been filed on behalf of investors who purchased Juno Therapeutics, Inc.

S&P 500, Dow Barely Beat Records in Little-Changed Session

S&P 500, Dow Barely Beat Records in Little-Changed Session

Crude oil kept markets under pressure on Wednesday after erasing big gains achieved over the previous session.

6 Big Stocks to Add to Your Buy List -- Plus 1 to Avoid

6 Big Stocks to Add to Your Buy List -- Plus 1 to Avoid

Here's a technical look at how to trade some of the most active stocks on the market right now.

Stocks Mixed After Fed's Beige Book Reports 'Modest' Growth in U.S.

Stocks Mixed After Fed's Beige Book Reports 'Modest' Growth in U.S.

Stocks are mixed Wednesday after the latest reading on the U.S. economy shows a steady state of growth.

Stocks Struggle for Direction as Crude Extends Decline

Stocks Struggle for Direction as Crude Extends Decline

Stocks struggle to determine direction on Wednesday as Wall Street takes a slight pause after two days of record-making runs.

Juno Therapeutics (JUNO) Stock Surges After FDA Lifts Clinical Hold

Juno Therapeutics (JUNO) Stock Surges After FDA Lifts Clinical Hold

Juno Therapeutics (JUNO) stock is surging in early-morning trading as a result of the FDA lifting the clinical hold placed on 'its lead pivotal trial' that resulted in two deaths.

Juno Therapeutics to Resume Drug Study

Juno Therapeutics to Resume Drug Study

Juno Therapeutics shares are soaring following news that a study of an experimental treatment for leukemia has been allowed to resume.

Stock Futures on Pause After Wall Street's Record-Making Run

Stock Futures on Pause After Wall Street's Record-Making Run

Stock futures make smaller moves higher on Wednesday as Wall Street takes a pause after two days of record-making runs.

Morning Movers: JUNO, AMZN, VRX, MIK

Morning Movers: JUNO, AMZN, VRX, MIK

Juno Therapeutics allowed to resume drug trial while Valeant's largest shareholder exits.

U.S. Stocks Pause After Record Run, Transports Move Out of Correction

U.S. Stocks Pause After Record Run, Transports Move Out of Correction

U.S. Stocks are taking a breather after hitting fresh record highs this week.

July 13 Premarket Briefing: 10 Things You Should Know

July 13 Premarket Briefing: 10 Things You Should Know

U.S. stock futures are rising slightly Wednesday following Tuesday's action that saw U.S. benchmarks finish at record highs.

Futures Rein In After Records Set; Asia Steps Up

Futures Rein In After Records Set; Asia Steps Up

Maybe investors aren't so gung-ho after three days of gains and record closes.

Juno Shares Jump in After-Hours Trading as FDA Removes Clinical Hold on JCAR015 Phase 2 Trial

Juno Shares Jump in After-Hours Trading as FDA Removes Clinical Hold on JCAR015 Phase 2 Trial

Five days after the federal agency had halted the clinical trial, the Seattle biopharma company said it will testing the leukemia drug candidate.

Juno Therapeutics To Resume JCAR015 Phase II ROCKET Trial

Juno Therapeutics To Resume JCAR015 Phase II ROCKET Trial

Juno Therapeutics, Inc. (Nasdaq: JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, today announced that the U.

SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into Juno Therapeutics Inc. For Possible Securities Law Violations And Encourages Investors To Contact The Firm For Additional Information

SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into Juno Therapeutics Inc. For Possible Securities Law Violations And Encourages Investors To Contact The Firm For Additional Information

The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible securities law violations by certain officers and directors of Juno Therapeutics Inc.

INVESTOR ALERT: Hagens Berman Investigating Possible Securities Law Violations By Certain Officers Of Juno Therapeutics Inc.

INVESTOR ALERT: Hagens Berman Investigating Possible Securities Law Violations By Certain Officers Of Juno Therapeutics Inc.

Hagens Berman Sobol Shapiro LLP alerts investors in Juno Therapeutics Inc.

S&P 500 Soars to Near Record Close as Jobs Report Brings Relief Over U.S. Economy

S&P 500 Soars to Near Record Close as Jobs Report Brings Relief Over U.S. Economy

Wall Street closed out the holiday-shortened week with a bang. Stocks bagged major gains after a blowout jobs report brought relief over the state of the U.S. economy.

S&P 500 Hovers at Records as Jobs Report Brings Economic Confidence

S&P 500 Hovers at Records as Jobs Report Brings Economic Confidence

Stocks jump Friday after a blockbuster jobs report assures investors recent weakness was an aberration.

Juno Therapeutics (JUNO) Stock Will Rise Again, RBC's Yee Tells CNBC

Juno Therapeutics (JUNO) Stock Will Rise Again, RBC's Yee Tells CNBC

Shares of Juno Therapeutics (JUNO) will bounce back from hitting extreme lows after its clinical study on a chemotherapy drug was halted, RBC's Michael Yee said on CNBC today.

Midday Report: Banks Rally; U.S. Stocks Jump on Upbeat Jobs

Midday Report: Banks Rally; U.S. Stocks Jump on Upbeat Jobs

U.S. stocks jumped after the latest reading on the U.S. labor market brought relief over the strength of the economy.

Stocks Extend Gains After Blockbuster Jobs Report

Stocks Extend Gains After Blockbuster Jobs Report

Stocks jump Friday morning after the latest reading on the U.S. labor market brings relief over the strength of the economy.

Juno Therapeutics (JUNO) Stock Downgraded at JPMorgan

Juno Therapeutics (JUNO) Stock Downgraded at JPMorgan

Juno Therapeutics’ (JUNO) stock rating was cut to ‘neutral’ from ‘overweight’ at JPMorgan after the biopharma company’s clinical trial was put on hold after patient deaths.

Stock Futures Move Higher as Labor Market Rebounds in June

Stock Futures Move Higher as Labor Market Rebounds in June

Stock futures move higher on Friday morning after the latest read on the U.S. labor market shows 287,000 jobs added to the U.S. economy in June.

Analysts' Actions -- Citigroup, CF Industries, Juno Therapeutics, AT&T and More

Analysts' Actions -- Citigroup, CF Industries, Juno Therapeutics, AT&T and More

Here are Friday's top research calls, including an upgrade for CF Industries, and downgrades for Citigroup, Juno Therapeutics and AT&T.

Assessing the Impact of Juno's Cancer CAR-T Stumble on Biotech Stocks

Assessing the Impact of Juno's Cancer CAR-T Stumble on Biotech Stocks

Juno Therapeutics reminds investors yet again that the business of biotech -- developing new medicines that are effective and reasonably safe -- is hard to get right.